Prime minister gives backing to more transparent drug trial dataBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8333 (Published 07 December 2012) Cite this as: BMJ 2012;345:e8333
- Adrian O’Dowd
David Cameron has added his support to efforts to ensure much greater availability of data from drug companies’ trials.
However, a leading expert has criticised Cameron for not making more of a commitment on forcing companies to publish all their clinical data.
The issue of drug companies not submitting all trial data was raised in the House of Commons on 5 December by Richard Bacon, the Conservative MP for South Norfolk.
The BMJ’s open data campaign (bmj.com/tamiflu) is aimed at securing appropriate and necessary independent scrutiny of data from clinical trials after the failure of the drug company Roche to fulfil its promise made in 2009 to release …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial